“showed a trend”

Time spent doing reconstructive surgery did not statistically significantly influence overall breast aesthetic score but showed a trend toward higher scoring ( P = 0.12).

Differences between groups were observed, as MSCs from COPD patients secreted significantly higher amounts of IL-6 and showed a trend towards higher IL-8 secretion (p=0.12) ( figure 3b ).

Similarly, the average number of cells per somite showed a trend toward an increase in the experimental group compared to controls (control vs. experiment: 237 ± 107 vs. 550 ± 117, p = 0.12, Figure 6c ), indicating that NAD(H) may promote the proliferation of PSM‐like progenitor cells.

Multivariable analysis showed a trend toward decreased odds of an abnormal contrast swallow when a speech-language pathologist was present during the examination (OR =0.448, 95% CI: 0.165–1.215, P=0.12).

In the group treated with carboplatin, the results showed a trend towards worse survival in TTF-1 − patients, with an OS of 1 month (95% CI: 0–2.3) compared to 4 months (95% CI: 0–10.4) in TTF-1 + patients (P=0.12).

In the 3 liver lesions that we isolated, VIM transcripts were significantly up-regulated ( P < 0.05 ), ZEB1 and ZEB2 transcript levels showed a trend to increase ( P < 0.12 and P < 0.25, respectively) (Fig. 3i ).

RFS Kaplan‐Meier curves and log‐rank testing showed a trend towards decreased ( P = .120) survival probability in high ADI in the p16‐positive population with a 5‐year RFS of 64.5% relative to 76.8% in the low ADI group, though this difference was not significant ( Figure 2 ).

JDM patients receiving corticosteroid treatment showed a trend for a higher frequency of CD40L induced IL-10+ B cells (mean 19.5% vs 14.4%, p = 0.12).

None of the vitamin D status subgroups were significantly different from one another for any of the severity of illness scores ( Table 4 ); although, SOFA showed a trend ( p = 0.12).

PFS was similar in both treatment arms, whereas OS showed a trend in favor of the panitumumab-containing arm (hazard ratio for death, 0.67; 95% CI, 0.41 to 1.11; p = 0.12).

Correlation between EME and RT ( Figure 2 ) showed no strong association except for the 2 and 8 h time points postfeeding, although the 8 h time point showed a trend ( P = 0.12) in LR cows.

The latency to escape also showed a trend to decrease in Yueju-treated mice in this system ( P = 0.12).

Similarly, CST reduction showed a trend favoring the ranibizumab group (−61.3 μm [−128.7 to + 6.1] vs. + 29.4 μm [−18.2 to + 77.0], p = 0.12).

Scintillation counts showed a trend for increased 3 H-glucose signal in IRβ-expressing cells (Student’s t -test; p = 0.120), which exhibited ∼30% more uptake than control cells ( Figure 1E ).

2.7% of placebo (HR 0.61, 95% CI 0.38-0.99, P = 0.04), while nonfatal MI showed a trend toward reduction (2.9% vs. 3.9%, HR 0.74, 95% CI 0.51-1.08, P = 0.12).

However, with the 5% and 50% cutoff values, the T-PD-L1 (+) group showed a trend of disadvantage in survival over the T-PD-L1 (−) group (p=0.12 and p=0.11).

For ROM, the Asian subgroup (1 study with 2 comparisons) showed no significant improvement (SMD = 0.01, 95% CI: −0.50 to 0.51; p = 0.98), and the non-Asian subgroup (2 studies with 3 comparisons) showed a trend toward improvement (SMD = 0.40, 95% CI: −0.10 to 0.89; p = 0.12), both with no heterogeneity (I 2 = 0%), identical to the overall ROM meta-analysis (I 2 = 0%).

Meta-regression showed a trend toward lower CBT efficacy for positive symptoms with a higher SZA disorder proportion (β = +0.10 SMD per 10% increase in AP; p = 0.12), though it was not statistically significant.

The inclusion of center-based cluster effects showed a trend towards ( P =0.12) improved model fit compared with fitting the same model using ordinary logistic regression with no clustering.

Although AMPCP treatment in the NI condition showed a trend toward increased LD area, this difference was not statistically significant ( p = 0.1203).

MYC breaks showed a trend for inferior EFS (HR 1.601, 95% CI 0.879–2.915, p = 0.1206) and statistically significantly reduced OS (HR 2.531, 95% CI 1.240–5.166, p = 0.0083; Fig. 1c, d ).

On day 12, although the individual PGF 2 α and PGE 2 levels showed a trend of increase and decrease, respectively, these changes were not statistically significant compared with those in the control group (PGF 2α : 201.40 pg/mg, p = 0.121; PGE 2 : 459.20 pg/mg, p = 0.134).

Subgroup analysis of patients ≥60 years showed a trend toward improved 2-year OS with fludarabine/cyclophosphamide/total body irradiation (Flu/Cy/TBI) versus fludarabine/busulfan: 71% versus 53% (HR = 0.47, p = 0.121).

The extent of intraoperative decrease showed a trend towards a significant higher reduction in the on-pump group when compared to the OPCAB (26.1±11.6% (mean ± SD ) vs. 19.1±15.6%; p = 0.121).

Although not statistically significant, individuals who did not know or reported not drinking tested potable water showed a trend toward a lower risk (adjusted OR = 0.29, 95% CI: 0.06–1.39, p = 0.121).